SMAD5

Across TCGA pan-cancer cohorts, SMAD5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SMAD5 data layer compared with 23 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SMAD5 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SMAD5 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, GBM, and LUAD are the cancer types where SMAD5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	IV	0.951	0.381	.006	16	view →
GBM	OS	Tertile	All	0.715	0.440	.001	16	view →
LUAD	DFS	Tertile	III,IV	0.364	0.750	.024	6	view →
CCRCC	DFS	Tertile	All	0.617	0.886	.023	5	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.814	.027	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SMAD5–PDAC (OS)

Open the PDAC breakdown →